BR0113906A - Modulação de respostas de células t mediadas por il-2 e il-15 - Google Patents
Modulação de respostas de células t mediadas por il-2 e il-15Info
- Publication number
- BR0113906A BR0113906A BR0113906-1A BR0113906A BR0113906A BR 0113906 A BR0113906 A BR 0113906A BR 0113906 A BR0113906 A BR 0113906A BR 0113906 A BR0113906 A BR 0113906A
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- agent
- cell death
- receptor
- mediated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
"MODULAçãO DE RESPOSTAS DE CéLULAS T MEDIADAS POR IL-2 E IL-15". A presente invenção refere-se, em parte, em estudos de expressão de subunidades de receptores de IL-2 e IL-15 por ciclagem de células T in vivo. Em uma modalidade, a invenção em geral apresenta novas combinações de antagonistas de IL-2 e IL-15 e métodos de supressão da resposta imunológica pela administração desses antagonistas. Em todos os casos, a supressão é obtida pela administração de um primeiro agente que orienta uma molécula de IL-15 ou um receptor de IL-15 (IL-15R) e um segundo agente que orienta uma molécula de IL-2 ou um receptor de IL-2 (IL-2R). Mais genericamente, a invenção apresenta novas combinações de agentes que, quando administradas a um paciente (ou a um transplante ex vivo), reduzem o números de células T reativas a antígenos. Por exemplo, a invenção apresenta composições (por exemplo, composições farmaceuticamente aceitáveis) que incluem dois ou mais agentes, todos promotores da morte de células T. Alternativamente, a composição pode conter pelo menos um agente que promova a morte de células T e pelo menos um agente que iniba a proliferação de células T. O agente que promove a morte de células T pode ser AICD (morte de células induzida por ativação), morte passiva de células, ADCC (citotoxicidade mediada por células dependentes de anticorpo) ou CDC (citotoxicidade direcionada para complemento).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23225100P | 2000-09-14 | 2000-09-14 | |
PCT/US2001/028612 WO2002022805A2 (en) | 2000-09-14 | 2001-09-14 | Modulation of il-2- and il-15-mediated t cell responses |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0113906A true BR0113906A (pt) | 2004-12-07 |
Family
ID=22872402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0113906-1A BR0113906A (pt) | 2000-09-14 | 2001-09-14 | Modulação de respostas de células t mediadas por il-2 e il-15 |
Country Status (16)
Country | Link |
---|---|
US (2) | US20020114781A1 (pt) |
EP (2) | EP2123672A1 (pt) |
JP (1) | JP2004525076A (pt) |
CN (1) | CN1317301C (pt) |
AT (1) | ATE427318T1 (pt) |
AU (1) | AU2001292645A1 (pt) |
BR (1) | BR0113906A (pt) |
CA (1) | CA2422294C (pt) |
DE (1) | DE60138222D1 (pt) |
ES (1) | ES2322936T3 (pt) |
HK (1) | HK1061408A1 (pt) |
IL (1) | IL154925A0 (pt) |
MX (1) | MXPA03002278A (pt) |
RU (1) | RU2280255C2 (pt) |
WO (1) | WO2002022805A2 (pt) |
ZA (1) | ZA200302933B (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
US20050084967A1 (en) * | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
CA2513905A1 (en) * | 2003-01-31 | 2004-08-19 | Albor Biologics, Inc. | Immune regulation based on the targeting of early activation molecules |
DE602004031681D1 (de) * | 2003-07-21 | 2011-04-14 | Transgene Sa | Multifunktionelle Cytokine |
DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
CA2553883C (en) | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
EP1899364B1 (en) | 2005-05-17 | 2020-02-19 | University of Connecticut | Compositions and methods for immunomodulation in an organism |
EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
NZ569541A (en) * | 2006-01-13 | 2012-05-25 | Us Gov Health & Human Serv | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
WO2007124331A2 (en) * | 2006-04-19 | 2007-11-01 | Virginia Commonwealth University | Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors |
US20110020269A1 (en) * | 2007-05-08 | 2011-01-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
CA2690825C (en) | 2007-05-11 | 2019-02-12 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
NZ582330A (en) | 2007-06-27 | 2012-05-25 | Marinepolymer Tech Inc | COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF |
JP2009065938A (ja) * | 2007-09-14 | 2009-04-02 | Matsumoto Shika Univ | タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法 |
RU2551229C2 (ru) * | 2009-02-27 | 2015-05-20 | Новартис Аг | Способы селекции эукариотических клеток, экспрессирующих гетерологичный белок |
WO2011020047A1 (en) | 2009-08-14 | 2011-02-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
KR20140020228A (ko) | 2010-09-21 | 2014-02-18 | 알토 바이오사이언스 코포레이션 | 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법 |
US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
BR112013018046B1 (pt) | 2011-01-18 | 2023-01-31 | Bioniz, Llc | Conjugado peptídico, composição farmacêutica, métodos in vitro para bloquear sinalização por um ou mais membros de família citocina-yc e para inibir ligação de citocina-yc a subunidade-yc e uso de conjugado peptídico ou de composição farmacêutica |
PL3578201T3 (pl) * | 2012-06-28 | 2023-09-11 | University Of Central Florida Research Foundation Incorporated | Metody i kompozycje dla naturalnych komórek cytotoksycznych |
US11401312B2 (en) | 2013-04-19 | 2022-08-02 | Cytune Pharma | Cytokine derived treatment with reduced vascular leak syndrome |
US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
EP3673915A1 (en) | 2014-06-30 | 2020-07-01 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
KR20170035910A (ko) * | 2014-08-11 | 2017-03-31 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 변형된 il-2 변이체 |
HUE056544T2 (hu) | 2015-10-09 | 2022-02-28 | Bioniz Llc | Gamma-C-citokin aktivitás modulálása |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
WO2017096262A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
CN106591368A (zh) * | 2016-10-12 | 2017-04-26 | 郑州大学 | 携带il‑15r/il‑15融合基因的b亚群腺病毒11载体及其构建和用途 |
EP3529263A4 (en) | 2016-10-21 | 2020-07-08 | Altor BioScience Corporation | MULTIMERIC MOLECULES BASED ON IL-15 |
EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
RU2698048C2 (ru) * | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
WO2021222178A1 (en) * | 2020-04-27 | 2021-11-04 | The Trustees Of Indiana University | Adjunct therapy for suppressing immune response against gene therapy |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
CN114773433B (zh) * | 2022-06-23 | 2022-09-06 | 北京肿瘤医院(北京大学肿瘤医院) | 一种cd25靶向多肽、分子探针及应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5011684A (en) | 1985-09-05 | 1991-04-30 | Beth Israel Hospital Association | Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
MY108267A (en) | 1991-01-16 | 1996-09-30 | Schering Corp | Use of interleukin-10 in adoptive immunotherapy of cancer |
IL101353A0 (en) * | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
WO1994006473A1 (en) | 1992-09-18 | 1994-03-31 | Schering Corporation | Restoration of immunocompetency to t helper cells in hiv infected patients |
US5747024A (en) | 1993-03-08 | 1998-05-05 | Immunex Corporation | Vaccine adjuvant comprising interleukin-15 |
US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
US5574138A (en) | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
IL111004A (en) * | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
WO1997041232A1 (en) * | 1996-04-26 | 1997-11-06 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
ES2187946T3 (es) * | 1997-02-21 | 2003-06-16 | Vlaams Interuniv Inst Biotech | Uso de interleucina-15. |
DE19823351A1 (de) | 1997-05-16 | 1998-12-10 | Krause Hans | Mittel zur Verhinderung der Zellapoptose bei Krankheiten |
-
2001
- 2001-09-14 IL IL15492501A patent/IL154925A0/xx unknown
- 2001-09-14 EP EP09004784A patent/EP2123672A1/en not_active Withdrawn
- 2001-09-14 US US09/953,323 patent/US20020114781A1/en not_active Abandoned
- 2001-09-14 AU AU2001292645A patent/AU2001292645A1/en not_active Abandoned
- 2001-09-14 ES ES01973022T patent/ES2322936T3/es not_active Expired - Lifetime
- 2001-09-14 BR BR0113906-1A patent/BR0113906A/pt not_active IP Right Cessation
- 2001-09-14 AT AT01973022T patent/ATE427318T1/de not_active IP Right Cessation
- 2001-09-14 CN CNB018185339A patent/CN1317301C/zh not_active Expired - Fee Related
- 2001-09-14 EP EP01973022A patent/EP1349873B1/en not_active Expired - Lifetime
- 2001-09-14 WO PCT/US2001/028612 patent/WO2002022805A2/en active Application Filing
- 2001-09-14 DE DE60138222T patent/DE60138222D1/de not_active Expired - Lifetime
- 2001-09-14 JP JP2002527247A patent/JP2004525076A/ja active Pending
- 2001-09-14 CA CA2422294A patent/CA2422294C/en not_active Expired - Fee Related
- 2001-09-14 MX MXPA03002278A patent/MXPA03002278A/es not_active Application Discontinuation
- 2001-09-14 RU RU2003110571/15A patent/RU2280255C2/ru not_active IP Right Cessation
-
2003
- 2003-04-14 ZA ZA200302933A patent/ZA200302933B/en unknown
- 2003-12-30 US US10/749,699 patent/US7579439B2/en not_active Expired - Fee Related
-
2004
- 2004-04-07 HK HK04102483.6A patent/HK1061408A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2004525076A (ja) | 2004-08-19 |
CN1478098A (zh) | 2004-02-25 |
CN1317301C (zh) | 2007-05-23 |
ATE427318T1 (de) | 2009-04-15 |
DE60138222D1 (de) | 2009-05-14 |
EP1349873B1 (en) | 2009-04-01 |
ZA200302933B (en) | 2004-07-14 |
EP1349873A2 (en) | 2003-10-08 |
US20040185048A1 (en) | 2004-09-23 |
ES2322936T3 (es) | 2009-07-02 |
MXPA03002278A (es) | 2004-12-03 |
RU2280255C2 (ru) | 2006-07-20 |
CA2422294C (en) | 2012-12-04 |
EP2123672A1 (en) | 2009-11-25 |
AU2001292645A1 (en) | 2002-03-26 |
HK1061408A1 (en) | 2004-09-17 |
CA2422294A1 (en) | 2002-03-21 |
US20020114781A1 (en) | 2002-08-22 |
WO2002022805A2 (en) | 2002-03-21 |
IL154925A0 (en) | 2003-10-31 |
US7579439B2 (en) | 2009-08-25 |
WO2002022805A3 (en) | 2003-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0113906A (pt) | Modulação de respostas de células t mediadas por il-2 e il-15 | |
FI974268A (fi) | Flavanolignaanien käyttö lääkkeiden, joilla on lisääntymistä torjuvaa vaikutusta kohdussa, munasarjoissa ja rintarauhasessa, valmistamiseksi | |
FR2714378B1 (fr) | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. | |
HUP0104390A2 (hu) | Alfa-2B vagy alfa-2B/2C adrenerg receptorokra nézve szelektív agonista aktivitással rendelkező imidazolszármazékok és alkalmazásuk | |
BRPI0113042B8 (pt) | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato | |
HUP0001170A2 (hu) | Hatóanyagként enzimidazol-2-karbamát-származékokat tartalmazó, vírusfertőzések és rák kezelésére alkalmas gyógyszerkészítmények | |
BR0209709A (pt) | Composições hipotensivas de lipìdio e timolol e métodos de uso das mesmas | |
BR0316310A (pt) | Composições farmacêuticas tendo um veìculo modificado | |
BRPI9607851B8 (pt) | combinação e formulação farmacêutica. | |
CA2622879A1 (en) | Use of a3 adenosine receptor agonist in osteoarthritis treatment | |
KR920702217A (ko) | 말라리아 치료 조성물 | |
DE60039921D1 (de) | Hochaffine kleinmolekülige c5a-rezeptor-modulatoren | |
BR9507846A (pt) | Composição farmacéutica estável e fortemente concentrada de principio ativo da classe dos taxóides escolhido entre o docetaxol ou os derivados do docetaxol processo de preparação desta composição e utilização de uma solução congelada ou liofilizada | |
ATE284698T1 (de) | Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten | |
DK1303278T3 (da) | Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme | |
ATE277639T1 (de) | Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten | |
DE60008590D1 (de) | Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern | |
CA2357114A1 (en) | Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder | |
ES2147796T3 (es) | Composicion para el tratamiento o la prevencion del herpes. | |
KR870010871A (ko) | 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법 | |
BR0005319A (pt) | Tratamento combinado para depressão e ansiedade | |
DE60008589D1 (de) | Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten | |
PT1100463E (pt) | Novas formulacoes injectaveis contendo ramoplanina | |
KR900017599A (ko) | 종양 치료용 약학 조성물 | |
BR0215498A (pt) | Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009. |